Clinical Trial Update: Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin for management of hepatitis C in patients with end-stage kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hepatitis C

Drugs mentioned

• Ombitasvir/Paritaprevir/Ritonavir + Ribavirin

Snippet

Sponsor: Assiut University | Conditions: End-stage Renal Disease, HCV Coinfection | Phase 4 | Status: COMPLETED